<DOC>
	<DOCNO>NCT01433133</DOCNO>
	<brief_summary>This Phase I-II , open-label , single center , uncontrolled , dose-escalation study . The trial conduct Israel Tel Aviv Sourasky Medical Center . All subject receive autologous InfraDure Biopump ( micro-organ dermis process ex vivo transduce genetic construct contain gene interferon ) tissue implant intend provide sustain production delivery therapeutic level INF twenty four ( 24 ) week follow INFRADURE Biopump implantation . Follow continue total two year post INFRADURE Biopump implantation</brief_summary>
	<brief_title>Safety Biological Activity InfraDure Biopump Secreting Sustained Interferon HCV Patients</brief_title>
	<detailed_description>Medgenics Inc. Medgenics Medical Israel Ltd. develop INFRADURE , autologous dermal biopump capable sustain secretion therapeutic INF body , use small tissue explant patient 's skin . The INFRADURE biopump produce micro-organ ( MO ) , typically measure 30 mm length 1.5-2.5 mm diameter , harvest directly patient 's dermis local anesthesia . The micro-organ viably maintain ex-vivo extend period time standard culture condition . INFRADURE Biopumps , produce ex vivo transduction MOs Helper Dependent Adenoviral INF vector ( HDAd-INF ) , express secrete INF . INFRADURE Biopump monitor ex vivo prior re-implantation , attain true INF dosing . The INFRADURE Biopump subsequently implant subcutaneously back patient order provide continuous delivery know amount INF . Each implant autologous INFRADURE Biopump remain localized skin , accessible , necessary , remove ablated time . The entire process harvest implantation require 10-14 day</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Signed patient consent form Genotype 3 chronic HCV detectable HCV RNA No previous treatment HCV infection Hepatitis B human immunodeficiency virus negative screen visit Able willing follow contraception requirement Screening laboratory value , test , physical exam within acceptable range Current enrollment another investigational device drug study Anticipated inability complete clinic visit comply study procedure History , current medical condition , could impact safety subject study Autoimmune hepatitis , suspect hepatocellular carcinoma , decompensated liver disease , know liver disease HCV Alcoholism substance abuse &lt; 6 documented month sobriety Known allergy sensitivity interferon ribavirin Any condition , opinion Investigator , would make subject unsuitable enrollment could interfere subject participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>